Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL)

Journal of Proteomics

Volumn 74, Issue 6, 2011, Pages 843-857

  Jiang, Nan ^a   Kham, Shirley Kow Yin ^a   Koh, Grace Shimin ^a   Suang Lim, Joshua Yew ^a   Ariffin, Hany ^b   Chew, Fook Tim ^c   Yeoh, Allen Eng Juh ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

2 DE; Childhood ALL; PCNA; Prednisolone; Prognostic biomarkers

Indexed keywords

BIOLOGICAL MARKER; COFILIN 1; CYCLINE; PREDNISOLONE; PROTEASOME; REGULATOR PROTEIN; VOLTAGE DEPENDENT ANION CHANNEL 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER PATIENT; CELL CYCLE REGULATION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IDENTIFICATION KEY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; COFILIN 1; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 79955474907     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.034     Document Type: Article

References (34)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Dordelmann M., Reiter A., Borkhardt A., Ludwig W.D., Gotz N., Viehmann S., et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999, 94:1209-1217.
3. Felice M.S., Zubizarreta P.A., Alfaro E.M., Sackmann-Muriel F. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol 2001, 23:411-415.
4. Schrappe M., Arico M., Harbott J., Biondi A., Zimmermann M., Conter V., et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730-2741.
5. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Korholz D., et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21:3262-3268.
6. Pui C.H., Dahl G.V., Rivera G., Murphy S.B., Costlow M.E. The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. Leuk Res 1984, 8:579-585.
7. Prokop A., Wieder T., Sturm I., Essmann F., Seeger K., Wuchter C., et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000, 14:1606-1613.
8. Krajinovic M., Labuda D., Mathonnet G., Labuda M., Moghrabi A., Champagne J., et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002, 8:802-810.
9. Ramakers-van Woerden N.L., Pieters R., Slater R.M., Loonen A.H., Beverloo H.B., van Drunen E., et al. In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol 2001, 112:680-690.
10. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
11. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
12. Herbert B.R., Molloy M.P., Gooley A.A., Walsh B.J., Bryson W.G., Williams K.L. Improved protein solubility in two-dimensional electrophoresis using tributyl phosphine as reducing agent. Electrophoresis 1998, 19:845-851.
13. Blum H., Beier H., Gross H. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987, 8:93-99.
14. Huang C., Zhang X., Lin Q., Xu X., Hu Z., Hew C.L. Proteomic analysis of shrimp white spot syndrome viral proteins and characterization of a novel envelope protein VP466. Mol Cell Proteomics 2002, 1:223-231.
15. Bell S.P., Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem 2002, 71:333-374.
16. Johnson A., O'Donnell M. Cellular DNA replicases: components and dynamics at the replication fork. Annu Rev Biochem 2005, 74:283-315.
17. Moldovan G.L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell 2007, 129:665-679.
18. Jaskulski D., deRiel J.K., Mercer W.E., Calabretta B., Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988, 240:1544-1546.
19. Liu Y.C., Marraccino R.L., Keng P.C., Bambara R.A., Lord E.M., Chou W.G., et al. Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle. Biochemistry 1989, 28:2967-2974.
20. Boldizsar F., Talaber G., Szabo M., Bartis D., Palinkas L., Nemeth P., et al. Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells. Immunobiology 2010, 215:521-526.
21. Lipworth B.J. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000, 356:87-89.
22. Song I.H., Buttgereit F. Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 2006, 246:142-146.
23. Alaiya A.A., Franzen B., Auer G., Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000, 21:1210-1217.
24. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
25. Shoshan-Barmatz V., Keinan N., Zaid H. Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr 2008, 40:183-191.
26. Yuan S., Fu Y., Wang X., Shi H., Huang Y., Song X., et al. Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J 2008, 22:2809-2820.
27. Abu-Hamad S., Sivan S., Shoshan-Barmatz V. The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc Natl Acad Sci USA 2006, 103:5787-5792.
28. Godbole A., Varghese J., Sarin A., Mathew M.K. VDAC is a conserved element of death pathways in plant and animal systems. Biochim Biophys Acta 2003, 1642:87-96.
29. Kuehn L., Dahlmann B. Structural and functional properties of proteasome activator PA28. Mol Biol Rep 1997, 24:89-93.
30. Dahlmann B. Proteasomes. Essays Biochem 2005, 41:31-48.
31. Rechsteiner M., Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol 2005, 15:27-33.
32. Ahn K., Erlander M., Leturcq D., Peterson P.A., Fruh K., Yang Y. In vivo characterization of the proteasome regulator PA28. J Biol Chem 1996, 271:18237-18242.
33. dos Remedios C.G., Chhabra D., Kekic M., Dedova I.V., Tsubakihara M., Berry D.A., et al. Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 2003, 83:433-473.
34. Moon A., Drubin D.G. The ADF/cofilin proteins: stimulus-responsive modulators of actin dynamics. Mol Biol Cell 1995, 6:1423-1431.